NYSE: AGL
agilon health, inc.CIK 0001831097 · Misc Health Services
Our business is transforming healthcare by empowering the primary care physicians (“PCP”) to be the agents for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost and patient… About this business →
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
agilon health holds routine annual meeting; directors elected, auditor and pay approved
3 material changes detected. Sign up free to read the summary.
Agilon Health narrowly avoids NYSE delisting via 1-for-25 reverse split; interim CEOs in place
5 material changes detected. Sign up free to read the summary.
Partner
Trade AGL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
agilon health reports Q1 2026 earnings results
2 material changes detected. Sign up free to read the summary.
agilon health names Tim O'Rourke CEO with equity tied to $50-$150 stock price targets
5 material changes detected. Sign up free to read the summary.
agilon health executes 1-for-25 reverse stock split, shares begin trading March 31
4 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed May 6, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 1,420 | 1,533 |
| Operating expenses: | ||
| General and administrative | 54.2 | 66.0 |
| Total operating expenses | 1,416 | 1,555 |
| Operating income | 4.0 | (22.1) |
| Interest expense | 1.8 | 1.5 |
| Other income/(expense), net | 16.0 | 9.3 |
| Income before income taxes | 29.9 | (1.7) |
| Income tax expense/(benefit) | 0.03 | 0.2 |
| Net income | 48.9 | 12.1 |
| Basic earnings per share | 2.95 | 0.73 |
| Diluted earnings per share | 2.94 | 0.73 |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 140.0 | 136.9 |
| Short-term investments | 91.4 | 230.1 |
| Prepaid expenses and other current assets | 118.4 | 42.4 |
| Other current assets | 971.3 | 1,241 |
| Total current assets | 1,321 | 1,651 |
| Property, plant and equipment, net | 24.9 | 28.1 |
| Operating lease right-of-use assets, net | 5.2 | 9.7 |
| Identifiable intangible assets, net | 62.4 | 68.2 |
| Goodwill | 24.1 | |
| Deferred income taxes and other assets | 96.4 | 161.7 |
| TOTAL ASSETS | 1,505 | 1,933 |
| Current liabilities: | ||
| Current portion of long-term debt | 14.7 | 34.9 |
| Other current liabilities | 1,258 | 1,340 |
| Total current liabilities | 1,272 | 1,375 |
| Long-term debt | 15.3 | — |
| Operating lease liabilities | 3.4 | 7.1 |
| Deferred income taxes and other liabilities | 35.9 | 57.9 |
| Total liabilities | 1,324 | 1,433 |
| Shareholders' equity: | ||
| Common stock | 0.2 | 4.1 |
| Capital in excess of stated value | 2,110 | 2,070 |
| Accumulated other comprehensive income (loss) | 0.5 | 0.5 |
| Retained earnings (deficit) | (1,929) | (1,575) |
| Total shareholders' equity | 181.4 | 500.3 |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 1,505 | 1,933 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | 23.7 | (32.0) |
| Investing Activities: | ||
| Net cash from investing activities | 19.3 | (23.1) |
| Financing Activities: | ||
| Net cash from financing activities | (5.1) | (0.2) |
| Net increase/(decrease) in cash | 37.9 | (55.2) |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗
View AI report for this filing
About agilon health, inc.
Source: Item 1 (Business) from the 10-K filed February 25, 2026. Description as filed by the company with the SEC.
ITEM 1. Business
Overview
Our business is transforming healthcare by empowering the primary care physicians (“PCP”) to be the agents for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost and patient experience when provided with the right infrastructure and payment model. Through our combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, we believe we are poised to revolutionize healthcare for seniors across communities throughout the United States (“U.S.”). We believe our purpose-built model provides the necessary capabilities, capital and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. Our model operates by primarily forming risk-bearing entities (“RBEs”) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners’ attributed patients (or global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs.
Our company was formed in 2016, and we established our inaugural partnership with an anchor physician group in 2017. Our ability to rapidly build scaled positions in local communities has allowed us to grow to 28 anchor physician groups and 30 geographies as of December 31, 2025. As of December 31, 2025, the PCPs on our platform serve approximately 511,000 MA members and 114,000 Medicare fee-for-service (“FFS”) beneficiaries through nine Accountable Care Organizations (“ACOs”) through our participation in the Centers for Medicare & Medicaid Services’ (“CMS”) Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model and Medicare Shared Savings Program (“MSSP,” and together with ACO REACH, the “CMS ACO Models”) through its equity method investments.
Read full description ↓
On November 5, 2025, we received written notice (the “Notice”) from the NYSE informing us that we are no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of our common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 4, 2025 (the “Price Criteria for Capital or Common Stock”).
We can regain compliance at any time within the six-month period following receipt of the Notice if, on the last trading day of any calendar month during the cure period (or the last trading day of the cure period), we have a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the prior 30 trading-day period ending on the last trading day of the applicable calendar month or the cure period. To regain compliance with the Price Criteria for Capital or Common Stock, we are pursuing a reverse stock split, subject to approval by our stockholders. We expect to seek stockholder approval at our special meeting to be held March 17, 2026. Under the NYSE Listed Company Manual, if we determine that we will cure the stock price deficiency by taking an action that will require stockholder approval, such as a reverse stock split, and we receive stockholder approval no later than our next general meeting of stockholders, the price condition will be deemed cured if, following stockholder approval and implementation of the approved action, the share price promptly exceeds $1.00 per share and the share price remains above that level for at least the following 30 trading days. See the risk entitled “The listing of shares of our common stock does not currently comply with the continued listing requirements of the NYSE, and if the NYSE delists our common stock, it could have an adverse impact on the trading, liquidity and market price of our common stock” under “